China's medical products administrator approved Grand Pharmaceutical's (HKG:0512) application for a phase 3 trial for its prostate cancer treatment, according to a Wednesday filing with the Hong Kong bourse.
The company will recruit 500 participants to the TLX591's phase 3 trial, seen to take place in multiple locations including China, the US, Australia, and New Zealand, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.